MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Announcing a new article publication for BIO Integration journal. Clinical trials bridge basic research and clinical application, serving as essential steps in drug development. This review examines ...
Trogenix’s proprietary dual-payload AAV gene therapy; TGX-007 leverages Trogenix’s precision synthetic super-enha ...
Daraxonrasib is the first investigational agent in a novel class of RAS (ON) multi-selective inhibitors designed to address a diverse and broad spectrum of RAS variants. In the randomized Phase 3 ...
Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia, an area with no approved ...
Morning Overview on MSN
A daraxonrasib trial just held pancreatic cancer in check for 8.5 months in most patients — twice as long as standard chemo for tumors that spread after first-line tr…
Pancreatic cancer is the third-leading cause of cancer death in the United States, and for patients whose tumors spread after ...
2don MSN
Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trials
Toregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II ...
Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ...
We are delighted to receive this Horizon Europe grant, which is a further validation of both our scientific approach ...
IgA reductions sustained at 12 weeks after a single dose of JADE101 >70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results